Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2016 (2016), Article ID 7625827, 10 pages
http://dx.doi.org/10.1155/2016/7625827
Review Article

Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia

Hematology, Department of Specialty Medicine, Ospedale Santa Maria di Ca’ Foncello, Piazza Ospedale 1, 31100 Treviso, Italy

Received 26 July 2015; Accepted 15 October 2015

Academic Editor: Dominik Wolf

Copyright © 2016 Federico Mosna and Michele Gottardi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Arber, J. Vardiman, R. Brunning et al., “Acute myeloid leukemia with recurrent genetic abnormalities,” in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, S. H. Swerlow, E. Campo, N. L. Harris, and etal, Eds., pp. 110–123, IARC Press, Lyon, France, 2008. View at Google Scholar
  2. P. Paschka, “Core binding factor acute myeloid leukemia,” Seminars in Oncology, vol. 35, no. 4, pp. 410–417, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Greaves and C. C. Maley, “Clonal evolution in cancer,” Nature, vol. 481, no. 7381, pp. 306–313, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Kreso and J. E. Dick, “Evolution of the cancer stem cell model,” Cell Stem Cell, vol. 14, no. 3, pp. 275–291, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Lapidot, C. Sirard, J. Vormoor et al., “A cell initiating human acute myeloid leukaemia after transplantation into SCID mice,” Nature, vol. 367, no. 6464, pp. 645–648, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Shackleton, “Normal stem cells and cancer stem cells: similar and different,” Seminars in Cancer Biology, vol. 20, no. 2, pp. 85–92, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. D. C. Taussig, F. Miraki-Moud, F. Anjos-Afonso et al., “Anti-CD38 antibody—mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells,” Blood, vol. 112, no. 3, pp. 568–575, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. D. C. Taussig, J. Vargaftig, F. Miraki-Moud et al., “Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34 fraction,” Blood, vol. 115, no. 10, pp. 1976–1984, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. W. Lane and D. G. Gilliland, “Leukemia stem cells,” Seminars in Cancer Biology, vol. 20, no. 2, pp. 71–76, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. R. B. Walter, F. R. Appelbaum, E. H. Estey, and I. D. Bernstein, “Acute myeloid leukemia stem cells and CD33-targeted immunotherapy,” Blood, vol. 119, no. 26, pp. 6198–6208, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Ishikawa, S. Yoshida, Y. Saito et al., “Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region,” Nature Biotechnology, vol. 25, no. 11, pp. 1315–1321, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Marusyk and K. Polyak, “Tumor heterogeneity: causes and consequences,” Biochimica et Biophysica Acta, vol. 1805, no. 1, pp. 105–117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Quintana, M. Shackleton, M. S. Sabel, D. R. Fullen, T. M. Johnson, and S. J. Morrison, “Efficient tumour formation by single human melanoma cells,” Nature, vol. 456, no. 7222, pp. 593–598, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. F. Greaves and J. Wiemels, “Origins of chromosome translocations in childhood leukaemia,” Nature Reviews Cancer, vol. 3, no. 9, pp. 639–649, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Gentles, S. K. Plevritis, R. Majeti, and A. A. Alizadeh, “Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia,” The Journal of the American Medical Association, vol. 304, no. 24, pp. 2706–2715, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. The Cancer Genome Atlas Research Network, “Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia,” The New England Journal of Medicine, vol. 368, no. 22, pp. 2059–2074, 2013. View at Publisher · View at Google Scholar
  17. P. C. Nowell, “The clonal evolution of tumor cell populations,” Science, vol. 194, no. 4260, pp. 23–28, 1976. View at Publisher · View at Google Scholar · View at Scopus
  18. L. M. F. Merlo, J. W. Pepper, B. J. Reid, and C. C. Maley, “Cancer as an evolutionary and ecological process,” Nature Reviews Cancer, vol. 6, no. 12, pp. 924–935, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. P. J. Fialkow, J. W. Singer, W. H. Raskind et al., “Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia,” The New England Journal of Medicine, vol. 317, no. 8, pp. 468–473, 1987. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Nucifora, R. A. Larson, and J. D. Rowley, “Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission,” Blood, vol. 82, no. 3, pp. 712–715, 1993. View at Google Scholar · View at Scopus
  21. J. Jurlander, M. A. Caligiuri, T. Ruutu et al., “Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia,” Blood, vol. 88, no. 6, pp. 2183–2191, 1996. View at Google Scholar · View at Scopus
  22. T. Miyamoto, K. Nagafuji, K. Akashi et al., “Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia,” Blood, vol. 87, no. 11, pp. 4789–4796, 1996. View at Google Scholar · View at Scopus
  23. M. R. Corces-Zimmerman, W.-J. Hong, I. L. Weissman, B. C. Medeiros, and R. Majeti, “Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 7, pp. 2548–2553, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Shima, T. Miyamoto, Y. Kikushige et al., “The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell,” Experimental Hematology, vol. 42, no. 11, pp. 955–965, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Q. Wang, D. W. L. Chin, J. Y. Chooi et al., “Cbfb deficiency results in differentiation blocks and stem/progenitor cell expansion in hematopoiesis,” Leukemia, vol. 29, no. 3, pp. 753–757, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. J. A. L. Yin, M. A. O'Brien, R. K. Hills, S. B. Daly, K. Wheatley, and A. K. Burnett, “Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial,” Blood, vol. 120, no. 14, pp. 2826–2835, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Perea, A. Lasa, A. Aventín et al., “Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)],” Leukemia, vol. 20, no. 1, pp. 87–94, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Gary Gilliland and J. D. Griffin, “The roles of FLT3 in hematopoiesis and leukemia,” Blood, vol. 100, no. 5, pp. 1532–1542, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Wichmann, I. Quagliano-Lo Coco, Ö. Yildiz et al., “Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors,” Leukemia, vol. 29, no. 2, pp. 279–289, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. A. V. Krivtsov, D. Twomey, Z. Feng et al., “Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9,” Nature, vol. 442, no. 7104, pp. 818–822, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. C. T. Jordan and M. L. Guzman, “Mechanisms controlling pathogenesis and survival of leukemic stem cells,” Oncogene, vol. 23, no. 43, pp. 7178–7187, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. L. I. Shlush, S. Zandi, A. Mitchell et al., “Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia,” Nature, vol. 506, no. 7488, pp. 328–333, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Goyama and J. C. Mulloy, “Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects,” International Journal of Hematology, vol. 94, no. 2, pp. 126–133, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. N. A. Speck and D. G. Gilliland, “Core-binding factors in haematopoiesis and leukaemia,” Nature Reviews Cancer, vol. 2, no. 7, pp. 502–513, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Okuda, J. van Deursen, S. W. Hiebert, G. Grosveld, and J. R. Downing, “AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis,” Cell, vol. 84, no. 2, pp. 321–330, 1996. View at Publisher · View at Google Scholar · View at Scopus
  36. Q. Wang, T. Stacy, J. D. Miller et al., “The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo,” Cell, vol. 87, no. 4, pp. 697–708, 1996. View at Google Scholar
  37. K. Lam and D.-E. Zhang, “RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis,” Frontiers in Bioscience, vol. 17, no. 3, pp. 1120–1139, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Bresciani, B. Carrington, S. Wincovitch et al., “CBFβ and RUNX1 are required at 2 different steps during the development of hematopoietic stem cells in zebrafish,” Blood, vol. 124, no. 1, pp. 70–78, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. L. M. Kelly and D. G. Gilliland, “Genetics of myeloid leukemias,” Annual Review of Genomics and Human Genetics, vol. 3, pp. 179–198, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Cabezas-Wallscheid, V. Eichwald, J. de Graaf et al., “Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mouse model,” EMBO Molecular Medicine, vol. 5, no. 12, pp. 1804–1820, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. L. H. Castilla, L. Garrett, N. Adya et al., “The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia,” Nature Genetics, vol. 23, no. 2, pp. 144–146, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Yan, E. Kanbe, L. F. Peterson et al., “A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis,” Nature Medicine, vol. 12, no. 8, pp. 945–949, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Alcalay, N. Meani, V. Gelmetti et al., “Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair,” Journal of Clinical Investigation, vol. 112, no. 11, pp. 1751–1761, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Mandoli, A. A. Singh, P. W. T. C. Jansen et al., “CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia,” Leukemia, vol. 28, no. 4, pp. 770–778, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. L. M. Calvi, G. B. Adams, K. W. Weibrecht et al., “Osteoblastic cells regulate the haematopoietic stem cell niche,” Nature, vol. 425, no. 6960, pp. 841–846, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Zhang, C. Niu, L. Ye et al., “Identification of the haematopoietic stem cell niche and control of the niche size,” Nature, vol. 425, no. 6960, pp. 836–841, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Méndez-Ferrer, T. V. Michurina, F. Ferraro et al., “Mesenchymal and haematopoietic stem cells form a unique bone marrow niche,” Nature, vol. 466, no. 7308, pp. 829–834, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Van Overstraeten-Schlögel, Y. Beguin, and A. Gothot, “Role of stromal-derived factor-1 in the hematopoietic-supporting activity of human mesenchymal stem cells,” European Journal of Haematology, vol. 76, no. 6, pp. 488–493, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. S. K. Nilsson, H. M. Johnston, G. A. Whitty et al., “Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells,” Blood, vol. 106, no. 4, pp. 1232–1239, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Stier, Y. Ko, R. Forkert et al., “Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size,” Journal of Experimental Medicine, vol. 201, no. 11, pp. 1781–1791, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. R. L. Driessen, H. M. Johnston, and S. K. Nilsson, “Membrane-bound stem cell factor is a key regulator in the initial lodgment of stem cells within the endosteal marrow region,” Experimental Hematology, vol. 31, no. 12, pp. 1284–1291, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. B. Heissig, K. Hattori, S. Dias et al., “Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of Kit-ligand,” Cell, vol. 109, no. 5, pp. 625–637, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Dar, O. Kollet, and T. Lapidot, “Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice,” Experimental Hematology, vol. 34, no. 8, pp. 967–975, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. F. Arai, A. Hirao, M. Ohmura et al., “Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche,” Cell, vol. 118, no. 2, pp. 149–161, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. A. W. Duncan, F. M. Rattis, L. N. DiMascio et al., “Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance,” Nature Immunology, vol. 6, no. 3, pp. 314–322, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Jin, K. J. Hope, Q. Zhai, F. Smadja-Joffe, and J. E. Dick, “Targeting of CD44 eradicates human acute myeloid leukemic stem cells,” Nature Medicine, vol. 12, no. 10, pp. 1167–1174, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. D. S. Krause, K. Lazarides, U. H. von Andrian, and R. A. van Etten, “Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells,” Nature Medicine, vol. 12, no. 10, pp. 1175–1180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Majeti, “Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells,” Oncogene, vol. 30, no. 9, pp. 1009–1019, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. E. Passegué, A. J. Wagers, S. Giuriato, W. C. Anderson, and I. L. Weissman, “Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates,” The Journal of Experimental Medicine, vol. 202, no. 11, pp. 1599–1611, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Yin and L. Li, “The stem cell niche in bone,” Journal of Clinical Investigation, vol. 116, no. 5, pp. 1195–1201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Ito, A. J. Barrett, A. Dutra et al., “Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells,” Stem Cell Research, vol. 14, no. 1, pp. 95–104, 2015. View at Publisher · View at Google Scholar · View at Scopus
  62. S. W. Lane, D. T. Scadden, and D. G. Gilliland, “The leukemic stem cell niche—current concepts and therapeutic opportunities,” Blood, vol. 114, no. 6, pp. 1150–1157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. C. D. Baldus, S. Liyanarachchi, K. Mrózek et al., “Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: amplification discloses overexpression of APP, ETS2, and ERG genes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 11, pp. 3915–3920, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. L. Jiang, G. Yu, W. Meng, Z. Wang, F. Meng, and W. Ma, “Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2,” Tumor Biology, vol. 34, no. 2, pp. 629–636, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Parmar, P. Mauch, J.-A. Vergilio, R. Sackstein, and J. D. Down, “Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 13, pp. 5431–5436, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. L. A. Gilbert and M. T. Hemann, “DNA damage-mediated induction of a chemoresistant niche,” Cell, vol. 143, no. 3, pp. 355–366, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Iwamoto, K. Mihara, J. R. Downing, C.-H. Pui, and D. Campana, “Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase,” The Journal of Clinical Investigation, vol. 117, no. 4, pp. 1049–1057, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. D. Grimwade and R. K. Hills, “Independent prognostic factors for AML outcome,” Hematology/the Education Program of the American Society of Hematology, vol. 1, pp. 385–395, 2009. View at Google Scholar
  69. H. F. Fernandez, Z. Sun, X. Yao et al., “Anthracycline dose intensification in acute myeloid leukemia,” The New England Journal of Medicine, vol. 361, no. 13, pp. 1249–1259, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. B. Löwenberg, G. J. Ossenkoppele, W. van Putten et al., “High-dose daunorubicin in older patients with acute myeloid leukemia,” The New England Journal of Medicine, vol. 361, no. 13, pp. 1235–1248, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. D. Grimwade, H. Walker, F. Oliver et al., “The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties,” Blood, vol. 92, no. 7, pp. 2322–2333, 1998. View at Google Scholar · View at Scopus
  72. D. Grimwade, R. K. Hills, A. V. Moorman et al., “Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials,” Blood, vol. 116, no. 3, pp. 354–365, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. M. L. Slovak, K. J. Kopecky, P. A. Cassileth et al., “Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest oncology group/Eastern cooperative oncology group study,” Blood, vol. 96, no. 13, pp. 4075–4083, 2000. View at Google Scholar · View at Scopus
  74. K. Mrózek, T. W. Prior, C. Edwards et al., “Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B study,” Journal of Clinical Oncology, vol. 19, no. 9, pp. 2482–2492, 2001. View at Google Scholar · View at Scopus
  75. J. C. Byrd, K. Mrózek, R. K. Dodge et al., “Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia group B (CALGB 8461),” Blood, vol. 100, no. 13, pp. 4325–4336, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. G. Marcucci, K. Mrózek, A. S. Ruppert et al., “Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5705–5717, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. F. R. Appelbaum, K. J. Kopecky, M. S. Tallman et al., “The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations,” British Journal of Haematology, vol. 135, no. 2, pp. 165–173, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. R. Cairoli, A. Beghini, G. Grillo et al., “Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study,” Blood, vol. 107, no. 9, pp. 3463–3468, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. F. Mosna, C. Papayannidis, G. Martinelli et al., “Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up,” American Journal of Hematology, vol. 90, no. 6, pp. 515–523, 2015. View at Publisher · View at Google Scholar
  80. B. Löwenberg, “Sense and nonsense of high-dose cytarabine for acute myeloid leukemia,” Blood, vol. 121, no. 1, pp. 26–28, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. P. Paschka and K. Döhner, “Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?” American Society of Hematology. Education Program, vol. 2013, no. 1, pp. 209–219, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. J. M. Rowe and B. Löwenberg, “Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug,” Blood, vol. 121, no. 24, pp. 4838–4841, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. A. K. Burnett, R. K. Hills, D. Milligan et al., “Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial,” Journal of Clinical Oncology, vol. 29, no. 4, pp. 369–377, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Castaigne, C. Pautas, C. Terré et al., “Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study,” The Lancet, vol. 379, no. 9825, pp. 1508–1516, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. A. K. Burnett, N. H. Russell, R. K. Hills et al., “Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia,” Journal of Clinical Oncology, vol. 30, no. 32, pp. 3924–3931, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. S. H. Petersdorf, K. J. Kopecky, M. Slovak et al., “A phase III study of gemtuzumab ozogamicin during induction and post-consolidation therapy in younger patients with acute myeloid leukemia,” Blood, vol. 121, no. 24, pp. 4854–4860, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Castaigne, “Why is it so difficult to use gemtuzumab ozogamicin?” Blood, vol. 121, no. 24, pp. 4813–4814, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. H. F. Fernandez, Z. Sun, M. R. Litzow et al., “Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin,” Blood, vol. 117, no. 20, pp. 5306–5313, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. H. Nakasone, K. Izutsu, S. Wakita, H. Yamaguchi, M. Muramatsu-Kida, and K. Usuki, “Autologous stem cell transplantation with PCR-negative graft would be associated with a favourable outcome in core-binding factor acute myeloid leukemia,” Biology of Blood and Marrow Transplantation, vol. 14, no. 11, pp. 1262–1269, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. H. Döhner, E. H. Estey, S. Amadori et al., “Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet,” Blood, vol. 115, no. 3, pp. 453–474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. J. C. Byrd, A. S. Ruppert, K. Mrózek et al., “Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461,” Journal of Clinical Oncology, vol. 22, no. 6, pp. 1087–1094, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. E. Paietta, “Minimal residual disease in acute myeloid leukemia: coming of age,” Hematology/American Society of Hematology. Education Program, vol. 1, pp. 35–42, 2012. View at Google Scholar
  93. D. Grimwade and S. D. Freeman, “Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for ‘prime time’?” Blood, vol. 124, no. 23, pp. 3345–3355, 2014. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Mohty and A. D. Ho, “In and out of the niche: perspectives in mobilization of hematopoietic stem cells,” Experimental Hematology, vol. 39, no. 7, pp. 723–729, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. P. S. Becker, “Growth factor priming in therapy of acute myelogenous leukemia,” Current Hematology Reports, vol. 3, no. 6, pp. 413–418, 2004. View at Google Scholar · View at Scopus
  96. A. K. Fielding, “Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: a broader range of options, improved outcomes, and more therapeutic dilemmas,” Hematology, vol. 35, pp. e352–e359, 2015. View at Google Scholar
  97. N. Boissel, A. Renneville, T. Leguay et al., “Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial,” Haematologica, vol. 100, no. 6, pp. 780–785, 2015. View at Publisher · View at Google Scholar